Shifting emphasis in Japan's reimbursement system
This article was originally published in Clinica
Executive Summary
Gaining reimbursement for medical devices in Japan can be a lengthy process for new products and, once achieved, prices generally decrease. A HIMA meeting on Doing Business in Japan & Asia, held in Washington, DC, on December 7th-8th, demystified the Japanese reimbursement system and shed light on some significant developments at the Ministry of Health and Welfare's Health Insurance Bureau.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.